<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516045</url>
  </required_header>
  <id_info>
    <org_study_id>201801002</org_study_id>
    <nct_id>NCT03516045</nct_id>
  </id_info>
  <brief_title>A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer</brief_title>
  <official_title>A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the clinical value of [18F]aluminum
      fluoride-1,4,7-triazacyclononane-1,4,7-triacetic
      acid-neurotensin（18F-AlF-NOTA-neurotensin）positron emission tomography / computed tomography
      (PET/CT) in patients with prostate cancer (PCa).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      18F-AlF-NOTA-neurotensin is a radioligand targeting the neurotensinreceptor, which is widely
      expressed on the cell surface of PCa. The radioligand can be used for the diagnosis and stage
      of the PCa. A total of 5 volunteers and 60 PCa patients will be subjected to a
      18F-AlF-NOTA-neurotensin PET/CT scan. The uptake of 18F-AlF-NOTA-neurotensin in organs and
      tumor lesions will be quantified as Standardized Uptake Values (SUVmax/SUVmean).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18F-AlF-NOTA-neurotensin PET/CT imaging of patients with Prostate Cancer</measure>
    <time_frame>12 months</time_frame>
    <description>The radioligand 18F-AlF-NOTA-neurotensin can be used to visualize prostate cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>18F-AlF-NOTA-neurotensin PET/CT prognostic factor for overall and disease specific survival</measure>
    <time_frame>24 months</time_frame>
    <description>The standard uptake value (SUV) of the 18F-AlF-NOTA-neurotensin in prostate cancer lesions is associated with Gleason score, staging and risk stratification of prostate cancer.
SUV (g/mL)=Cimg / (ID/BW) ; Cimg is the prostate cancer pixel intensities of a calibrated PET image (MBq/ml), ID is the injected dose or injected radioactivity (MBq),BW is the body weight (g) .
Gleason score of a prostate biopsy or radical prostatectomy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>18F-AlF-NOTA-neurotensin PET/CT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One injection of the radioligand 18F-AlF-NOTA-neurotensin Device: PET/CT Following injection of 18F-AlF-NOTA-neurotensin the participants will be subjected to whole body PET/CT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AlF-NOTA-neurotensin</intervention_name>
    <description>One injection of the radioligand 18F-AlF-NOTA-neurotensin</description>
    <arm_group_label>18F-AlF-NOTA-neurotensin PET/CT</arm_group_label>
    <other_name>18F-AlF-NOTA-NT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically and/or clinically confirmed and/or suspicious of PCa.

          2. Signed informed consent.

        Exclusion Criteria:

        Claustrophobia (unable to accept PET/CT scanning)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongxiang Tang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of PET Center,Xiangya Hospital,Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongxiang Tang, MD</last_name>
    <phone>+86 13549654360</phone>
    <email>yxtang@csu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shuo Hu, MD, Phd</last_name>
    <phone>+86 15874210819</phone>
    <email>hushuo_xy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of PET Center,Xiangya Hospital,Central South University</name>
      <address>
        <city>Changsha</city>
        <state>China, Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongxiang Tang, MD</last_name>
      <phone>+86 13549654360</phone>
      <email>yxtang@csu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Maschauer S, Einsiedel J, Hübner H, Gmeiner P, Prante O. (18)F- and (68)Ga-Labeled Neurotensin Peptides for PET Imaging of Neurotensin Receptor 1. J Med Chem. 2016 Jul 14;59(13):6480-92. doi: 10.1021/acs.jmedchem.6b00675. Epub 2016 Jun 30.</citation>
    <PMID>27336295</PMID>
  </reference>
  <reference>
    <citation>Wu Z, Li L, Liu S, Yakushijin F, Yakushijin K, Horne D, Conti PS, Li Z, Kandeel F, Shively JE. Facile Preparation of a Thiol-Reactive (18)F-Labeling Agent and Synthesis of (18)F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor-Positive Tumor. J Nucl Med. 2014 Jul;55(7):1178-84. doi: 10.2967/jnumed.114.137489. Epub 2014 May 22.</citation>
    <PMID>24854793</PMID>
  </reference>
  <reference>
    <citation>Deng H, Wang H, Wang M, Li Z, Wu Z. Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor. Mol Pharm. 2015 Aug 3;12(8):3054-61. doi: 10.1021/acs.molpharmaceut.5b00325. Epub 2015 Jul 21.</citation>
    <PMID>26162008</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>May 13, 2018</last_update_submitted>
  <last_update_submitted_qc>May 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>18F-AlF-NOTA-neurotensin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

